The FDA has proposed ending the use of a common ingredient found in many cold and allergy medicines — and some pharmacies ...

Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

U.S. farmers struggling with slumping incomes and depressed grain prices have been switching to cheaper generic pesticides ...

The FDA announced a proposal to remove oral phenylephrine – a common ingredient in many popular over-the-counter decongestants – from the market, citing evidence that it doesn't work.

It's still October and Amazon just wrapped up its fall Prime Day sale earlier this month, but it's never too early to start looking at Black Friday deals. Amazon offers one of the largest Black ...

GSK shares fell on Wednesday after the group's vaccine sales continued to disappoint in the third quarter. The drugmaker saw weaker-than-expected demand for its respiratory syncytial virus (RSV ...

The UK’s second-biggest pharmaceutical firm still saw 2% sales growth across the business after ... of thousands of lawsuits in the US over its discontinued heartburn drug Zantac earlier in October.

GSK did reiterate its financial guidance for the year, however, helped by demand for its cancer and HIV drugs: at constant exchange rates it's still expecting revenue growth of 7% to 9% ...

Notably, GSK’s previously sold antacid Zantac may have caused cancer in some patients. Naturally, this creates some legal risks for shareholders. So far, GSK has incurred a $2.2 billion charge ...

Indie game developer Lavabird and publisher First Break Labs have continued to keep the free Steam Next Fest demo for Warside up, as we now know the game's release date. During the event, the team ...

SMCI's over sold status brings about a rich capital appreciation ... deployment of AI-related products with the capex boom likely still in its nascency, triggering long-term tailwinds for data ...